cyproheptadine has been researched along with niacinamide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, G; Huang, N; Huang, XP; Lin, X; Peng, S; Roth, BL; Wang, S; Wang, SX; Wang, Y; Whaley, R; Zhang, G | 1 |
| Chen, CY; Chen, SC; Feng, CW; Feng, YM; Lee, MY; Lu, CL | 1 |
3 other study(ies) available for cyproheptadine and niacinamide
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.
Topics: Antineoplastic Agents; Benzenesulfonates; Cyproheptadine; Drug Approval; Drug Discovery; Ketanserin; Molecular Dynamics Simulation; Niacinamide; Phenylurea Compounds; Protein Conformation; Pyridines; Receptors, Serotonin; Sequence Homology, Amino Acid; Serotonin Antagonists; Sorafenib; United States; United States Food and Drug Administration; User-Computer Interface | 2012 |
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Cyproheptadine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |